Edition:
United Kingdom

Aralez Pharmaceuticals Inc (ARLZ.OQ)

ARLZ.OQ on NASDAQ Stock Exchange Global Select Market

1.39USD
20 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.39
Open
$1.41
Day's High
$1.41
Day's Low
$1.37
Volume
11,162
Avg. Vol
99,767
52-wk High
$2.98
52-wk Low
$0.95

Chart for

About

Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company's products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin,... (more)

Overall

Beta: --
Market Cap(Mil.): $156.43
Shares Outstanding(Mil.): 66.85
Dividend: --
Yield (%): --

Financials

  ARLZ.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -1.63 -- --
ROI: -31.71 14.84 14.38
ROE: -87.20 16.34 16.07

BRIEF-Aralez Pharmaceuticals Says Unit Entered Into Modification Of Contract

* ARALEZ PHARMA - UNIT ENTERED INTO MODIFICATION OF CONTRACT PURSUANT TO WHICH U.S. EXERCISED SECOND RENEWAL OPTION UNDER THAT VA NATIONAL CONTRACT

05 Apr 2018

BRIEF-Aralez Pharmaceuticals Inc - ‍On March 13, Board Appointed Michael Kaseta As Company's CFO - SEC Filing

* ARALEZ PHARMACEUTICALS INC - ‍ON MARCH 13, BOARD APPOINTED MICHAEL KASETA AS COMPANY'S CFO - SEC FILING Source text (http://bit.ly/2p8Z0x1) Further company coverage: (Reuters.Brief@thomsonreuters.com)

14 Mar 2018

BRIEF-Aralez Pharmaceuticals Posts Q4 Loss Per Share $0.68‍‍​

* ARALEZ ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

13 Mar 2018

BRIEF-Aralez Pharmaceuticals files for mixed shelf offering of up to $100 mln - SEC filing‍​

* Aralez Pharmaceuticals Inc - files for mixed shelf offering of up to $100 million - SEC filing‍​ Source text: (http://bit.ly/2zrTHPn) Further company coverage:

09 Nov 2017

BRIEF-Aralez sees 2018 net revenues $140 mln to $160 mln‍​

* Aralez announces third quarter 2017 financial results and achieves profitability on an adjusted EBITDA basis for the first time in the third quarter

09 Nov 2017

Earnings vs. Estimates